Pancreatic Ductal Adenocarcinoma Clinical Trials in Tampa, Florida

4 studies are recruiting for pancreatic ductal adenocarcinoma in Tampa, Florida right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations

    A first in human study to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of BLU-924 / SAR449336, a pan-KRAS inhibitor, in participants with advanced Pancreatic Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer harboring KRAS mutations.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Moffitt Cancer Center, Tampa, Florida
    Locations
    3 in total
    Run by
    Blueprint Medicines Corporation

    See if you can join NCT07629960 on ClinicalTrials.gov

  2. Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

    This study is to evaluate the safety, tolerability, and PK profiles of Elironrasib and Daraxonrasib as monotherapies and combination therapy in patients with KRAS G12C-mutated solid tumors.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Moffitt Cancer Center and Research Institute, Tampa, Florida
    Locations
    55 in total
    Run by
    Revolution Medicines, Inc.

    See if you can join NCT06128551 on ClinicalTrials.gov

  3. Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors

    The purpose of this platform study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON) inhibitors combined with Standard(s) of Care (SOC) or with novel agents. The current subprotocols include the following: Subprotocol A: RMC-6236 + 5…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Moffitt Cancer Center, Tampa, Florida
    Locations
    32 in total
    Run by
    Revolution Medicines, Inc.

    See if you can join NCT06445062 on ClinicalTrials.gov

  4. Pancreatic Cancer Early Detection Consortium

    The purpose of the Pancreatic Cancer Early Detection (PRECEDE) Consortium is to conduct research on multiple aspects of early detection and prevention of pancreatic ductal adenocarcinoma (PDAC) by establishing a multisite cohort of individuals with family history of PDAC and/or individuals carrying…

    Stage
    Not phased
    Ages
    18 to 90
    Site
    Moffitt Cancer Center, Tampa, Florida
    Locations
    60 in total
    Run by
    Arbor Research Collaborative for Health

    See if you can join NCT04970056 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.